Multimodality in Oncology: Are We There Yet?

Published on 14/04/26
Tags: Blog

In this thought leadership podcast episode, leading experts from clinical oncology and health technology take a clear-eyed look at where multimodality truly stands today. While widely recognized as the future of oncology, its translation into everyday clinical practice remains uneven and complex.

Multimodal cancer care is no longer a concept: it’s becoming a reality.

Hosted by Philippe Menu, MD, PhD, MBA, EVP, Chief Product Officer and Chief Medical Officer at SOPHiA GENETICS, this discussion brings together:

Pedram Razavi, MD, PhD, Breast Medical Oncologist and Director of the Liquid Biopsy and Cancer Genomics, MSK Biomarker Development Program at Memorial Sloan Kettering Cancer Center (MSKCC), offers a clinician’s view on multimodality, workflow realities, and decision-making at a top cancer center.
Matthew Lungren, MD, MPH, a professor of clinical AI at Stanford University and Health Technology Leader at Microsoft, shares insights on AI innovation, data infrastructure, and large-scale clinical deployment.

In this episode, you will explore:

What multimodality truly means in day-to-day oncology practice;
The key bottlenecks slowing the adoption of AI, including workflow friction, trust, data silos and governance;
Why innovation is progressing faster than its translation into routine care;
And a realistic three-year outlook on the multimodal and AI capabilities most likely to impact routine oncology care.

Listen to this thoughtful conversation to gain a grounded and clinically relevant perspective on the promise, the reality, and the future of multimodality in oncology.

Disclaimer notice
© 2026 SOPHiA GENETICS. All rights reserved. The opinions expressed during this podcast episode are those of the speakers and may or may not represent the opinions of SOPHiA GENETICS.

SOPHiA GENETICS products are for research use only, not for diagnostic procedures unless specified otherwise. Some SOPHiA GENETICS products or technologies described in this podcast episode are under development.

Sign Up To Our Newsletter

Enter your email address to join our mailing list and receive the latest news and updates from SOPHiA GENETICS. You can unsubscribe by using the link integrated with the communication at any time. By clicking to “sign up”, you agree that SOPHiA GENETICS will process your data in accordance with its Privacy Policy.

SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.

All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.

SOPHiA DDM™ Overview

SOPHiA DDM™ for Genomics

SOPHiA DDM™ for Radiomics

SOPHiA DDM™ for Multimodal

Professional Services